PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy
- PMID: 26678008
- DOI: 10.1016/j.jhep.2015.11.035
PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy
Abstract
Background & aims: Risk scores for hepatocellular carcinoma (HCC) developed in Asians offer poor-moderate predictability in Caucasian patients with chronic hepatitis B (CHB). This nine center cohort study aimed to develop and validate an accurate HCC risk score in Caucasian CHB patients treated with the current oral antivirals, entecavir/tenofovir.
Methods: We included 1815 adult Caucasians with CHB and no HCC at baseline who received entecavir/tenofovir for ⩾12 months. Using data from eight centers (derivation dataset, n=1325), a HCC risk score was developed based on multivariable Cox models and points system for simplification. Harrell's c-index was used as discrimination, bootstrap for internal validation and the data from the 9(th) and largest center (validation dataset, n=490) for external validation.
Results: The 5-year cumulative HCC incidence rates were 5.7% and 8.4% in the derivation and validation dataset, respectively. In the derivation dataset, age, gender, platelets and cirrhosis were independently associated with HCC. The PAGE-B score was developed based on age, gender and platelets (c-index=0.82, 0.81 after bootstrap validation). The addition of cirrhosis did not substantially improve the discrimination (c-index=0.84). The predictability of PAGE-B score was similar (c-index=0.82) in the validation dataset. Patients with PAGE-B ⩽9, 10-17, ⩾18 had 5-year cumulative HCC incidence rates of 0%, 3%, 17% in the derivation and 0%, 4%, 16% in the validation dataset.
Conclusion: PAGE-B, which is based only on baseline patients' age, gender and platelets, represents a simple and reliable score for prediction of the 5-year HCC risk in Caucasian CHB patients under entecavir/tenofovir.
Keywords: Entecavir; Hepatitis B; Hepatocellular carcinoma; Tenofovir.
Copyright © 2015 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
Similar articles
-
Modified PAGE-B score predicts the risk of hepatocellular carcinoma in Asians with chronic hepatitis B on antiviral therapy.J Hepatol. 2018 Nov;69(5):1066-1073. doi: 10.1016/j.jhep.2018.07.018. Epub 2018 Aug 1. J Hepatol. 2018. PMID: 30075230
-
Prediction model for hepatocellular carcinoma risk in treatment-naive chronic hepatitis B patients receiving entecavir/tenofovir.Eur J Gastroenterol Hepatol. 2019 Jul;31(7):865-872. doi: 10.1097/MEG.0000000000001357. Eur J Gastroenterol Hepatol. 2019. PMID: 30694912
-
Hepatocellular carcinoma prediction beyond year 5 of oral therapy in a large cohort of Caucasian patients with chronic hepatitis B.J Hepatol. 2020 Jun;72(6):1088-1096. doi: 10.1016/j.jhep.2020.01.007. Epub 2020 Jan 22. J Hepatol. 2020. PMID: 31981727
-
Risk of hepatocellular carcinoma in chronic hepatitis B: assessment and modification with current antiviral therapy.J Hepatol. 2015 Apr;62(4):956-67. doi: 10.1016/j.jhep.2015.01.002. Epub 2015 Jan 13. J Hepatol. 2015. PMID: 25595883 Review.
-
Clinical utility of hepatocellular carcinoma risk scores in chronic hepatitis B.Liver Int. 2020 Mar;40(3):484-495. doi: 10.1111/liv.14334. Epub 2020 Jan 7. Liver Int. 2020. PMID: 31884726 Review.
Cited by
-
Circulating predictive and diagnostic biomarkers for hepatitis B virus-associated hepatocellular carcinoma.World J Gastroenterol. 2016 Oct 7;22(37):8271-8282. doi: 10.3748/wjg.v22.i37.8271. World J Gastroenterol. 2016. PMID: 27729734 Free PMC article. Review.
-
Does Hepatocellular Carcinoma Surveillance Increase Survival in At-Risk Populations? Patient Selection, Biomarkers, and Barriers.Dig Dis Sci. 2020 Dec;65(12):3456-3462. doi: 10.1007/s10620-020-06550-6. Dig Dis Sci. 2020. PMID: 32860090 Free PMC article. Review.
-
Early warning of hepatocellular carcinoma in cirrhotic patients by three-phase CT-based deep learning radiomics model: a retrospective, multicentre, cohort study.EClinicalMedicine. 2024 Jul 5;74:102718. doi: 10.1016/j.eclinm.2024.102718. eCollection 2024 Aug. EClinicalMedicine. 2024. PMID: 39070173 Free PMC article.
-
Management of HBV and HBV/HDV-Associated Liver Cirrhosis.Visc Med. 2016 Apr;32(2):86-94. doi: 10.1159/000445518. Epub 2016 Apr 12. Visc Med. 2016. PMID: 27413725 Free PMC article. Review.
-
Transcriptomic Analysis of Hepatitis B Infected Liver for Prediction of Hepatocellular Carcinoma.Biology (Basel). 2023 Jan 26;12(2):188. doi: 10.3390/biology12020188. Biology (Basel). 2023. PMID: 36829466 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical